top of page
Search

GyroStim: Cutting-Edge Technology for Vestibular Rehabilitation

GyroStim is an advanced neurorehabilitation device that combines robot-controlled vestibular stimulation with visual, cognitive, and sensorimotor challenges to enhance recovery in patients with balance disorders and vestibular dysfunction. Built around a multi-axis rotational chair, GyroStim delivers precisely controlled motion while patients perform coordinated tasks designed to promote neuroplasticity and improve sensory integration. This multimodal approach aims to accelerate functional recovery beyond what conventional vestibular therapy alone often achieves.


The device delivers controlled, three-dimensional vestibular stimulation via a motorized chair that rotates along multiple axes. While the chair moves, patients often perform visuomotor tasks, cognitive challenges, and hand eye coordination tasks designed to simultaneously engage multiple neural systems involved in sensorimotor integration. By tightly dosing vestibular input and pairing it with task-specific engagement, GyroStim aims to amplify neuroplastic changes required for recovery.

This multimodal approach targets:

  • Vestibular nuclei and cerebellar circuits

  • Vestibulo-ocular reflex (VOR) pathways

  • Multisensory integration across visual, proprioceptive, and vestibular systems

  • Motor control and cognitive processing networks

By engaging these systems together, GyroStim seeks to overcome some limitations of traditional exercises, which often emphasize isolated components of rehabilitation.


FDA Clearance & Breakthrough Designation

GyroStim has received significant regulatory recognition:

  • As of April 27, 2022, GyroStim is FDA-cleared (510[k] K220231) as a medical device intended to assist in the treatment of balance disorders and vestibular dysfunction in adults. This clearance allows the device to be marketed and used clinically in appropriate patient populations as prescribed by trained medical professionals.

  • It also received the FDA Breakthrough Device designation in August of 2021, awarded to technologies that show a reasonable expectation of providing more effective treatment than current standard care.

Conditions That Can Benefit from GyroStim

GyroStim’s FDA clearance broadly covers vestibular dysfunction and balance disorders, and its use has been clinically applied to a wide range of conditions known to benefit from vestibular rehabilitation therapy (VRT). According to Gyrostim these include:

Neurological & Vestibular Conditions

  • Concussion / mTBI and Persistent Post-Concussion Syndrome

  • Traumatic Brain Injury (TBI)

  • Post-stroke vestibular dysfunction and balance deficits

  • Vestibular disorders such as vertigo, vestibular migraine, Mal de Débarquement Syndrome (MdDS), bilateral vestibular hypofunction (BVH), and PPPD

  • Benign Paroxysmal Positional Vertigo (BPPV)

Neurodegenerative & Movement Disorders

  • Parkinson’s disease

  • Multiple sclerosis (MS)

  • Other neurodegenerative conditions (e.g., ALS, Alzheimer’s, Huntington’s)

Neurodevelopmental & Sensory Integration Disorders

  • Cerebral palsy

  • Autism Spectrum Disorder (ASD)

  • Attention-Deficit/Hyperactivity Disorder (ADHD)

  • Down Syndrome

Age-Related & Systemic Conditions

  • Age-related balance dysfunction (presbystasis)

  • Autonomic nervous system disorders such as POTS and dysautonomia

  • Post-infectious conditions like Long COVID and Lyme disease

  • Chemo-related balance dysfunction and “chemo brain”

GyroStim’s multimodal approach targets symptoms including dizziness, imbalance, motion sensitivity, brain fog, fatigue, poor concentration, and gait instability—all common across these disorders. In a clinical setting at Carolina Functional Neurology Center we have seen improved patient outcomes in many of these conditions utilizing gyrostim within a patients treatment plan. 


Clinical Research & Evidence

Persistent Post-Concussion Syndrome (PPCS / mTBI)

A retrospective chart review compared adult patients with persistent symptoms after mild traumatic brain injury (mTBI) undergoing standard neurorehabilitation (SOC) versus SOC plus GyroStim therapy. Key findings included:

  • Patients treated with GyroStim had significantly greater reductions in symptom severity (measured via SCAT5) compared with those treated with SOC alone.

  • GyroStim patients showed more than double the balance improvement (Modified Balance Error Scoring System) and up to 17× higher therapeutic dose-response per session.

  • Adding GyroStim to standard therapy was associated with faster and more complete recovery trajectories than SOC alone.

These preliminary findings suggest that the technology-assisted stimulation can substantially enhance outcomes in persistent post-concussion populations.

Vestibular Dysfunction & Balance Disorders

In another retrospective comparison of adults with various vestibular dysfunctions—including concussion/mTBI, stroke, BPPV, PPPD, vestibular neuritis, unilateral and bilateral vestibular loss, and MdDS—GyroStim combined with standard vestibular therapy yielded:

  • Accelerated recovery rates compared to standard vestibular rehabilitation alone

  • Approximately four times faster clinical discharge when GyroStim was added to standard care

  • Significant improvements across validated clinical assessments

These early data support the potential value of integrating GyroStim into comprehensive rehabilitation protocols, though larger controlled clinical trials are still needed to further quantify benefits and optimal treatment protocols.

Conclusion

GyroStim represents a novel application of technology in vestibular rehabilitation, leveraging controlled vestibular stimulation and multimodal engagement to drive neuroplasticity and functional recovery. With FDA clearance and Breakthrough Device status, it offers clinicians a tool to enhance standard therapies—particularly for patients with persistent balance and vestibular issues that have not fully responded to conventional approaches. As published clinical experience grows, GyroStim may become a central part of comprehensive care for a wide range of neurosensory conditions. 

References

  1. GyroStim clinical evidence summary, including retrospective chart review of PPCS and vestibular dysfunction outcomes. (https://www.gyrostim.com/clinical-evidence?utm_source=chatgpt.com) 

  2. FDA status information on GyroStim’s 510(k) clearance and Breakthrough Device designation. (https://www.gyrostim.com/fda?utm_source=chatgpt.com) 

  3. GyroStim product overview and clinical application description. (https://www.gyrostim.com/?utm_source=chatgpt.com) 

  4. Retrospective clinical data in FDA 510(k) summary showing balance score improvements compared to standard of care. (https://www.accessdata.fda.gov/cdrh_docs/pdf22/K220231.pdf?utm_source=chatgpt.com) 

 
 
bottom of page